Cantor Fitzgerald Forecasts Scholar Rock FY2025 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Scholar Rock in a research note issued to investors on Thursday, July 17th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($3.14) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Scholar Rock’s FY2026 earnings at ($2.72) EPS.

Several other brokerages have also issued reports on SRRK. Lifesci Capital upgraded shares of Scholar Rock to a “strong-buy” rating in a research report on Tuesday, June 3rd. Wedbush restated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, June 18th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $42.67.

Scholar Rock Stock Performance

Shares of SRRK opened at $40.72 on Monday. Scholar Rock has a 12-month low of $6.76 and a 12-month high of $46.98. The company has a current ratio of 10.25, a quick ratio of 10.25 and a debt-to-equity ratio of 0.16. The company has a market cap of $3.87 billion, a PE ratio of -16.09 and a beta of 0.33. The stock has a 50-day moving average price of $33.76 and a 200-day moving average price of $35.00.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). During the same period in the prior year, the firm posted ($0.59) earnings per share.

Institutional Trading of Scholar Rock

A number of institutional investors have recently made changes to their positions in SRRK. CWM LLC boosted its holdings in shares of Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company’s stock worth $32,000 after purchasing an additional 602 shares during the period. Federated Hermes Inc. bought a new position in Scholar Rock during the 1st quarter valued at approximately $71,000. GF Fund Management CO. LTD. lifted its holdings in Scholar Rock by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company’s stock worth $77,000 after buying an additional 430 shares during the period. Strs Ohio bought a new stake in shares of Scholar Rock in the 1st quarter worth approximately $77,000. Finally, AlphaQuest LLC grew its position in shares of Scholar Rock by 490.7% in the 1st quarter. AlphaQuest LLC now owns 5,417 shares of the company’s stock worth $174,000 after buying an additional 4,500 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Jeffrey S. Flier sold 20,316 shares of the company’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $32.24, for a total transaction of $654,987.84. Following the completion of the sale, the director directly owned 24,070 shares in the company, valued at $776,016.80. This represents a 45.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kristina Burow sold 5,400 shares of the business’s stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $160,488.00. Following the completion of the sale, the director directly owned 21,071 shares of the company’s stock, valued at approximately $626,230.12. This trade represents a 20.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,654 shares of company stock worth $3,265,961 in the last 90 days. Corporate insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.